https://doi.org/10.55788/9102f0d1
“Non-smoking women have a higher risk of lung cancer than non-smoking men,” stated Dr Renelle Myers (University of British Columbia, Canada). “Also, evidence indicates that air pollution is a major cause of lung cancer in non-smoking individuals [2].” The current study aimed to compare the cumulative 3-year versus 20-year exposure to particulate matter 2.5 (PM2.5) in newly diagnosed women with lung cancer who had never smoked. Data from a detailed residential history questionnaire was uploaded into a geographic information system that quantified PM2.5 with a high-spatial resolution global exposure model.
In total, 236 women with newly diagnosed lung cancer (46.7% EGFR-mutated) were analysed; 71.2% of the patients was Asian, 18.6% was White, and 10.2% was classified as ‘Other’. Interestingly, 188 patients were born outside of Canada and 96 of them were born . Among the foreign-born Canadians, the 3-year cumulative PM2.5 data showed that 2.1% of the participants had an exposure >10 μg/m3. This rate increased to 20.2% when observing the 20-year cumulative PM2.5 data. Of note, an effect of 3-year cumulative PM2.5 exposure on the incidence of EGFR mutations was observed (P=0.049), but this effect was not preserved when looking at the 20-year data (P=0.188).
Based on the current results, Dr Myers argued that the 20-year cumulative PM2.5 exposure data may underestimate the effects of PM2.5 during childhood and adolescence, given the fact that the average age of the included patients was 66.1 years and that most of the patients were foreign-born Canadians, raised in highly polluted areas of the world.
- Myers R, et al. Evaluation of outdoor air pollution in female non-smoking lung cancer patients. OA13.03, WCLC 2022, Vienna, Austria, 06–09 August.
- Tseng CH, et al. J Thoracic Oncol. 2019;14(5):784-792.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Interventions needed to address sexual health in lung cancer Next Article
Intensive co-located smoking cessation programme highly effective during lung screening »
« Interventions needed to address sexual health in lung cancer Next Article
Intensive co-located smoking cessation programme highly effective during lung screening »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles
January 28, 2022
Promising outlook for sugemalimab in non-small-cell lung cancer
August 17, 2022
Points of interest for radiologists screening for lung cancer
August 6, 2021
5-year PACIFIC data hold strong in NSCLC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com